Huai Nan Shi

This research aims to verify the accuracy, stability, and clinical usefulness of artificial intelligence (AI) algorithms for measuring heart function through echocardiography. The study involves collaboration with multiple medical centers and focuses on comparing AI measurements with those done manually by physicians of different experience levels. It also explores whether AI can reduce the time needed for echocardiogram analysis and improve clinical workflows, while assessing AI's performance in complex heart conditions such as cardiomyopathy and valve disease. The study collects echocardiographic data using Mindray ultrasonic machines, with AI and physicians at each center measuring key heart parameters including left and right ventricular size and function. AI and intermediate doctors complete measurements within one day of data collection, while senior physicians at the main research unit finalize their assessments within one month. The goal is to establish a standardized reference system for AI in ultrasound measurement and promote its use across various medical institutions. Participants aged 18 to 80 years with specific heart conditions or normal hearts are involved. Researchers measure heart chamber sizes and functions through echocardiography, comparing AI and physician results for consistency and accuracy. The study also monitors how AI-assisted measurements could optimize diagnosis time and medical resource use. The total duration of participant involvement depends on data collection and measurement timelines, with ongoing analysis to support AI's clinical application in cardiovascular care.

Researchers are evaluating ziltivekimab as a treatment for people living with heart failure and inflammation. This Phase 3 study compares ziltivekimab to a placebo in participants with heart failure who have mild to preserved ejection fraction and systemic inflammation. The study aims to assess the effect of ziltivekimab on cardiovascular death, heart failure hospitalization, or urgent heart failure visits over a period of up to 4 years. Participants will receive monthly injections of either ziltivekimab or a placebo using a pre-filled syringe or a pen-injector. The study medication is administered subcutaneously once a month for up to 4 years. The trial includes up to 20 clinic visits during which participants will be monitored and assessed. During the study, participants will use a study app on their phone to record all injections and complete questionnaires. Researchers will monitor participants for key outcomes like cardiovascular events and heart failure episodes from the time of randomization until the end of the study. Safety and health status will be regularly evaluated throughout the study period, which may last up to 48 months.

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects. The study staff may also contact the participants by phone. Participants also regularly answer questions about their well-being. The study does not have a fixed duration. It continues until there is enough data to see if the treatment is working.

Researchers are evaluating the effectiveness and safety of Sodium Oligomannate (GV-971) in treating mild to moderate Alzheimer's disease. This Phase 4, multi-center, randomized, double-blind, placebo-controlled study aims to confirm how GV-971 works in the body, identify known side effects from long-term use, and watch for any new adverse reactions to guide clinical use. Participants in the study will receive either GV-971 or a placebo, both taken orally, over a period of 36 weeks. The study measures changes from the beginning in cognitive function using the ADAS-cog/12 score and daily living activities using the ADCS-ADL23 score. During the trial, participants will undergo brain MRI scans to confirm Alzheimer's diagnosis and will be monitored through various assessments including cognitive and functional tests. Researchers will track safety and side effects throughout the 36 weeks to better understand the treatment's impact and tolerability.

Researchers are establishing a standardized clinical information database for liver cancer patients through a collaborative effort led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China (USTC). This database aims to support high-quality real-world clinical studies and research on hepatocellular carcinoma and related liver cancers. Participants may receive routine treatments such as surgical operations including resection, ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). They might also be treated with various anti-tumor drugs including immunologic, targeted, and chemotherapy medications. Treatments and clinical data are collected to enrich the database for future research. During the study, participants will provide blood samples and postoperative pathology residual samples and will be followed over time to monitor their health and treatment outcomes. The primary outcome measured is overall survival over 10 years. Participants must be willing to comply with follow-up visits and provide informed consent, ensuring comprehensive data collection for long-term analysis.

Researchers are comparing two types of total intravenous anesthesia—remimazolam and propofol—in patients who are at moderate to high risk and undergoing major elective noncardiac surgery under general anesthesia. This Phase 4 randomized controlled trial aims to determine if using remimazolam can increase the number of days patients are alive and out of the hospital within 30 days after surgery compared to propofol. The study focuses on patients aged 45 years and older with specific health risks undergoing surgeries expected to last more than 2 hours with postoperative stays longer than 2 days. Participants receive either remimazolam or propofol administered intravenously for both induction and maintenance of general anesthesia during their surgery. The trial is conducted across multiple centers and involves strict criteria to select patients with conditions such as coronary artery disease, stroke history, heart failure, diabetes, or other listed risks. The study excludes patients undergoing certain types of surgeries or with severe organ dysfunction to ensure safety and appropriate comparison. During the study, researchers will monitor patients for 30 days after surgery, focusing on the primary outcome of days alive and out of the hospital. Safety and recovery will be closely tracked, including the need for postoperative ventilatory support and any complications during the hospital stay. The total involvement includes surgery and follow-up assessments to evaluate the effectiveness and safety of the anesthesia methods in this patient population.

Researchers are investigating whether adding endovascular therapy (EVT) to the best medical management improves outcomes for adults who have had a minor stroke caused by a large blood vessel blockage in the brain and who experience worsening neurological symptoms more than 24 hours after stroke onset. The study focuses on patients with an ischemic stroke affecting the anterior circulation and evaluates the safety and effectiveness of EVT in this late time window. The study enrolls about 272 patients aged 18 years or older who have a minor stroke with a National Institutes of Health Stroke Scale (NIHSS) score less than 6, evidence of large vessel occlusion, and symptom progression within 7 days. Participants are randomly assigned to receive either best medical management alone, which includes monitoring vital signs and standard drug therapies, or best medical management plus EVT, which may involve mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty, or stenting. The study involves seven visits from randomization through 90 days to monitor progress. During the study, participants undergo assessments of neurological function, imaging tests, laboratory studies, and symptom evaluations at multiple time points up to 90 days. The primary outcome measured is the proportion of patients achieving good clinical outcomes 90 days after randomization based on a modified Rankin Scale score of 0 to 2. Safety is closely monitored by a Data and Safety Monitoring Board, and the trial follows ethical guidelines and regulatory standards. The study is expected to run from December 2023 to December 2025 at about 30 centers in China.

Researchers are evaluating the safety and effectiveness of atorvastatin in adults aged 18 to 80 years who have experienced spontaneous intracerebral hemorrhage (ICH). This multicenter, prospective, randomized, open-label, blinded end-point (PROBE) study plans to enroll 264 patients who arrive within 3 to 24 hours after symptom onset. The goal is to see if atorvastatin can improve recovery compared to standard medical treatment alone. Participants will be randomly assigned to one of two groups: one group will receive best medical treatment according to current ICH guidelines, and the other will receive the same treatment plus atorvastatin at a dose of 20 mg once daily for 21 days. Treatment is started within 48 hours of symptom onset or last known well time. The study focuses on patients with hematomas in the supratentorial brain region, with specific volume and coma scale criteria. During the study, participants will be monitored for functional outcomes, with the primary measure being the proportion of patients who have poor functional recovery at about 90 days, defined by a modified Rankin Scale score of 4 to 6. The study includes assessments through imaging to confirm diagnosis and careful tracking of symptoms and clinical status throughout the treatment and follow-up periods to evaluate safety and efficacy.